IMIPRAMINE PAMOATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C23H16O6.2C19H24N2
Molecular Weight	949.1841
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C13.CN(C)CCCN4C5=CC=CC=C5CCC6=CC=CC=C46.OC(=O)C7=CC8=CC=CC=C8C(CC9=C%10C=CC=CC%10=CC(C(O)=O)=C9O)=C7O

InChI

InChIKey=BPQZYOJIXDMZSX-UHFFFAOYSA-N

InChI=1S/C23H16O6.2C19H24N2/c24-20-16(14-7-3-1-5-12(14)9-18(20)22(26)27)11-17-15-8-4-2-6-13(15)10-19(21(17)25)23(28)29;2*1-20(2)14-7-15-21-18-10-5-3-8-16(18)12-13-17-9-4-6-11-19(17)21/h1-10,24-25H,11H2,(H,26,27)(H,28,29);2*3-6,8-11H,7,12-15H2,1-2H3

HIDE SMILES / InChI

Molecular Formula	C19H24N2
Molecular Weight	280.4073
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C23H16O6
Molecular Weight	388.3695
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.drugbank.ca/drugs/DB00458
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/087846s028,087844s027,087845s027lbl.pdf

Imipramine is a tricyclic antidepressant with general pharmacological properties similar to those of structurally related tricyclic antidepressant drugs such as amitriptyline and doxepin. A tertiary amine, imipramine inhibits the reuptake of serotonin more so than most secondary amine tricyclics, meaning that it blocks the reuptake of neurotransmitters serotonin and noradrenaline almost equally. With chronic use, imipramine also down-regulates cerebral cortical β-adrenergic receptors and sensitizes post-synaptic sertonergic receptors, which also contributes to increased serotonergic transmission. It takes approximately 2 - 4 weeks for antidepressants effects to occur. The onset of action may be longer, up to 8 weeks, in some individuals. It is also effective in migraine prophylaxis, but not in abortion of acute migraine attack. Imipramine works by inhibiting the neuronal reuptake of the neurotransmitters norepinephrine and serotonin. It binds the sodium-dependent serotonin transporter and sodium-dependent norepinephrine transporter preventing or reducing the reuptake of norepinephrine and serotonin by nerve cells. Depression has been linked to a lack of stimulation of the post-synaptic neuron by norepinephrine and serotonin. Slowing the reuptake of these neurotransmitters increases their concentration in the synaptic cleft, which is thought to contribute to relieving symptoms of depression. In addition to acutely inhibiting neurotransmitter re-uptake, imipramine causes down-regulation of cerebral cortical beta-adrenergic receptors and sensitization of post-synaptic serotonergic receptors with chronic use. This leads to enhanced serotonergic transmission. Used for relief of symptoms of depression and as temporary adjunctive therapy in reducing enuresis in children aged 6 years and older. May also be used to manage panic disorders, with or without agoraphobia, as a second line agent in ADHD, management of eating disorders, for short-term management of acute depressive episodes in bipolar disorder and schizophrenia, and for symptomatic treatment of postherpetic neuralgia.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Serum paraoxonase/arylesterase 1 31 Target ID: P27169 Gene ID: 5444.0 Gene Symbol: PON1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/23001316	Inhibitor 8504
Norepinephrine transporter 197 Target ID: CHEMBL222 Sources: https://www.drugbank.ca/drugs/DB00458	Inhibitor 8504	12.0 nM [Ki]
Serotonin transporter 183 Target ID: CHEMBL228 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18983139	Inhibitor 8504	3.2 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Depression 240 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/087846s028,087844s027,087845s027lbl.pdf	Primary		Approved 8583	Tofranil Approved Use Tofranil is used for: Treating depression. It is also used in some children to help reduce bedwetting. It may also be used for other conditions as determined by your doctor. Launch Date 1984

C_max

Value	Dose	Co-administered	Analyte	Population
24.5 ng/mL OTHER https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1016/S0009-9236%2897%2990062-X	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:		IMIPRAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
107 μg/L REVIEW https://pubmed.ncbi.nlm.nih.gov/2185906/	130 mg 1 times / day steady-state, oral dose: 130 mg route of administration: Oral experiment type: STEADY-STATE co-administered: Desipramine	Desipramine	IMIPRAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
427 ng × h/mL OTHER https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1016/S0009-9236%2897%2990062-X	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:		IMIPRAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
21.1 h OTHER https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1016/S0009-9236%2897%2990062-X	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:		IMIPRAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
12 h REVIEW https://pubmed.ncbi.nlm.nih.gov/2185906/	130 mg 1 times / day steady-state, oral dose: 130 mg route of administration: Oral experiment type: STEADY-STATE co-administered: Desipramine	Desipramine	IMIPRAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
22% REVIEW https://pubmed.ncbi.nlm.nih.gov/2185906/	130 mg 1 times / day steady-state, oral dose: 130 mg route of administration: Oral experiment type: STEADY-STATE co-administered: Desipramine	Desipramine	IMIPRAMINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
200 mg/day 1 times / day steady, oral Dose: 200 mg/day, 1 times / day Route: oral Route: steady Dose: 200 mg/day, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9023787	unhealthy, 18-70 years Health Status: unhealthy Age Group: 18-70 years Sources: https://pubmed.ncbi.nlm.nih.gov/9023787	Disc. AE: Nausea... AEs leading to discontinuation/dose reduction: Nausea (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/9023787
25 mg/day 1 times / day steady, oral Dose: 25 mg/day, 1 times / day Route: oral Route: steady Dose: 25 mg/day, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19653341	unhealthy, 42.6 ± 12.4 years Health Status: unhealthy Age Group: 42.6 ± 12.4 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/19653341	Disc. AE: Sleep disturbance, Urinary tract signs and symptoms NEC... AEs leading to discontinuation/dose reduction: Sleep disturbance (3 patients) Urinary tract signs and symptoms NEC (2 patients) Palpitations (2 patients) Anxiety (1 patient) Dry mouth (1 patient) Dizziness (3 patients) Flushing (1 patient) Constipation (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/19653341
75 mg/day 1 times / day steady, oral Recommended Dose: 75 mg/day, 1 times / day Route: oral Route: steady Dose: 75 mg/day, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/017090s078lbl.pdf	unhealthy, < 24 years Health Status: unhealthy Age Group: < 24 years Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/017090s078lbl.pdf	Disc. AE: Suicidal ideation... AEs leading to discontinuation/dose reduction: Suicidal ideation (grade 5) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/017090s078lbl.pdf

AEs

AE	Significance	Dose	Population
Nausea	1 patient Disc. AE	200 mg/day 1 times / day steady, oral Dose: 200 mg/day, 1 times / day Route: oral Route: steady Dose: 200 mg/day, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9023787	unhealthy, 18-70 years Health Status: unhealthy Age Group: 18-70 years Sources: https://pubmed.ncbi.nlm.nih.gov/9023787
Anxiety	1 patient Disc. AE	25 mg/day 1 times / day steady, oral Dose: 25 mg/day, 1 times / day Route: oral Route: steady Dose: 25 mg/day, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19653341	unhealthy, 42.6 ± 12.4 years Health Status: unhealthy Age Group: 42.6 ± 12.4 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/19653341
Constipation	1 patient Disc. AE	25 mg/day 1 times / day steady, oral Dose: 25 mg/day, 1 times / day Route: oral Route: steady Dose: 25 mg/day, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19653341	unhealthy, 42.6 ± 12.4 years Health Status: unhealthy Age Group: 42.6 ± 12.4 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/19653341
Dry mouth	1 patient Disc. AE	25 mg/day 1 times / day steady, oral Dose: 25 mg/day, 1 times / day Route: oral Route: steady Dose: 25 mg/day, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19653341	unhealthy, 42.6 ± 12.4 years Health Status: unhealthy Age Group: 42.6 ± 12.4 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/19653341
Flushing	1 patient Disc. AE	25 mg/day 1 times / day steady, oral Dose: 25 mg/day, 1 times / day Route: oral Route: steady Dose: 25 mg/day, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19653341	unhealthy, 42.6 ± 12.4 years Health Status: unhealthy Age Group: 42.6 ± 12.4 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/19653341
Palpitations	2 patients Disc. AE	25 mg/day 1 times / day steady, oral Dose: 25 mg/day, 1 times / day Route: oral Route: steady Dose: 25 mg/day, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19653341	unhealthy, 42.6 ± 12.4 years Health Status: unhealthy Age Group: 42.6 ± 12.4 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/19653341
Urinary tract signs and symptoms NEC	2 patients Disc. AE	25 mg/day 1 times / day steady, oral Dose: 25 mg/day, 1 times / day Route: oral Route: steady Dose: 25 mg/day, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19653341	unhealthy, 42.6 ± 12.4 years Health Status: unhealthy Age Group: 42.6 ± 12.4 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/19653341
Dizziness	3 patients Disc. AE	25 mg/day 1 times / day steady, oral Dose: 25 mg/day, 1 times / day Route: oral Route: steady Dose: 25 mg/day, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19653341	unhealthy, 42.6 ± 12.4 years Health Status: unhealthy Age Group: 42.6 ± 12.4 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/19653341
Sleep disturbance	3 patients Disc. AE	25 mg/day 1 times / day steady, oral Dose: 25 mg/day, 1 times / day Route: oral Route: steady Dose: 25 mg/day, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19653341	unhealthy, 42.6 ± 12.4 years Health Status: unhealthy Age Group: 42.6 ± 12.4 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/19653341
Suicidal ideation	grade 5 Disc. AE	75 mg/day 1 times / day steady, oral Recommended Dose: 75 mg/day, 1 times / day Route: oral Route: steady Dose: 75 mg/day, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/017090s078lbl.pdf	unhealthy, < 24 years Health Status: unhealthy Age Group: < 24 years Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/017090s078lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946		substrate 1388	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OCT2 779 OCT3 159 MATE1 415 MATE2 267	CYP2C19 1119 CYP1A2 1197 P-gp 2052 UGT2B10 131 UGT1A4 399 UGT1A3 470

Drug as perpetrator

Target	Modality	Activity
OCT2 782	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/19002438/	yes [IC50 6 uM]
MATE2 267	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/19164462/	yes [Ki 182.9 uM]
MATE1 416	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/19164462/	yes [Ki 42 uM]
OCT3 161	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/10966924/	yes [Ki 42 uM]

Drug as victim

Target	Modality	Activity
CYP1A2 1197	substrate 4014 Sources: https://academic.oup.com/jat/article/38/6/368/2797982	yes
CYP2C19 1119	substrate 4014 Sources: https://academic.oup.com/jat/article/38/6/368/2797982	yes
CYP2D6 1388	substrate 4014 Sources: https://academic.oup.com/jat/article/38/6/368/2797982	yes
CYP3A4 1946	substrate 4014 Sources: https://academic.oup.com/jat/article/38/6/368/2797982	yes
P-gp 2052	substrate 4014 Sources: https://academic.oup.com/ijnp/article/16/10/2259/653065	yes
UGT1A3 470	substrate 4014 Sources: https://sci-hub.do/10.1124/dmd.109.030981	yes
UGT1A4 399	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/20133892/	yes
UGT2B10 131	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/20133892/	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1571643/

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:47499	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:47499
ChemicalBook	CB1727489	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB1727489
MolPort	MolPort-001-783-692	https://www.molport.com/shop/molecule-link/MolPort-001-783-692
ZINC	ZINC000000020245	http://zinc15.docking.org/substances/ZINC000000020245

PubMed

Title	Date	PubMed
Hormonal responses to the 5-HT1A agonist buspirone in remitted endogenous depressive patients after long-term imipramine treatment.	2010-05	19762159
Prediction of phospholipidosis-inducing potential of drugs by in vitro biochemical and physicochemical assays followed by multivariate analysis.	2010-03	19786086
Imipramine enhances cell proliferation and decreases neurodegeneration in the hippocampus after transient global cerebral ischemia in rats.	2010-02-05	20036317
Sub-chronic administration of rimonabant causes loss of antidepressive activity and decreases doublecortin immunoreactivity in the mouse hippocampus.	2009-12-25	19819298
A new homogeneous high-throughput screening assay for profiling compound activity on the human ether-a-go-go-related gene channel.	2009-11-01	19583963
Medicine and psychiatry in Western culture: Ancient Greek myths and modern prejudices.	2009-10-07	19811642
Possible role of trazodone and imipramine in sleep deprivation-induced anxiety-like behavior and oxidative damage in mice.	2009-10-03	19798453
Suppressive effect of imipramine on vincristine-induced mechanical allodynia in mice.	2009-07	19571391
Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety/depression.	2009-05-28	19477151
Chronic administration of imipramine normalizes decreased sexual motivation and increased predisposition to catalepsy induced by propylthiouracil in rats.	2009-05	19340585
Behavioral changes in rats induced by a dipeptidyl peptidase IV inhibitor methionyl-2(S)-cyanopyrrolidine: experimental model of anxiety-depression disorder.	2009-03	19529845
Manifestation of psychiatric behaviors in a mouse model of griseofulvin-induced hepatic porphyria.	2008-12	19043281
Community-based randomised controlled trial evaluating falls and osteoporosis risk management strategies.	2008-11-04	18983670
[Chronic imipramine treatment normalizes decreased sexual motivation and high predisposition to catalepsy induced by propylthiouracil in rat].	2008-07-30	18661784
D-161, a novel pyran-based triple monoamine transporter blocker: behavioral pharmacological evidence for antidepressant-like action.	2008-07-28	18561912
Gene expression profiling in rat liver treated with compounds inducing phospholipidosis.	2008-06-15	18355885
Pharmacological separation of hEAG and hERG K+ channel function in the human mammary carcinoma cell line MCF-7.	2008-06	18497958
Chronic coadministration of carbamazepine together with imipramine produces antidepressant-like effects in an ACTH-induced animal model of treatment-resistant depression: involvement of 5-HT(2A) receptors?	2008-05	18255130
Temporal expression of brain-derived neurotrophic factor (BDNF) mRNA in the rat hippocampus after treatment with selective and mixed monoaminergic antidepressants.	2008-01-14	17950272
Hereditary diffuse gastric cancer: association with lobular breast cancer.	2008	18046629
Histone deacetylase 5 epigenetically controls behavioral adaptations to chronic emotional stimuli.	2007-11-08	17988634
In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid based methodologies.	2007-09	17567588
Curcumin reverses impaired hippocampal neurogenesis and increases serotonin receptor 1A mRNA and brain-derived neurotrophic factor expression in chronically stressed rats.	2007-08-08	17617388
[Chemico-toxicological analysis of haloperidol in blood with high-performance liquid chromatography in combined poisoning].	2007-06-30	17598448
Polypharmacy and EPS in a child; a case report.	2007	17514191
Influence of antidepressants on hemostasis.	2007	17506225
Molecular identification and functional characterization of rat multidrug and toxin extrusion type transporter 1 as an organic cation/H+ antiporter in the kidney.	2006-11	16928787
Mechanism of imipramine-induced seizures in amygdala-kindled rats.	2006-11	16914292
Recurrence of dilated cardiomyopathy after re-introduction of a tricyclic antidepressant.	2006-10	17100146
[Trazodone for the treatment of behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease: a retrospective study focused on the aggression and negativism in caregiving situations].	2006-06	16856516
Frequency of high-risk use of QT-prolonging medications.	2006-06	16178046
[Cardiac arrhythmia in amitriptyline poisoning in children].	2006-04-13	16607780
[Lack of antidepresant-like activity of some ligands of polyamine binding sites of NMDA receptors in models of depression].	2006-04-04	16579050
Antidepressant drugs activate SREBP and up-regulate cholesterol and fatty acid biosynthesis in human glial cells.	2006-03-13	16324787
Induction of neuroserpin expression in rat frontal cortex after chronic antidepressant treatment and electroconvulsive treatment.	2006-02	16637596
[Treatment of anxiety syndrome. A systematic literature review. Summary and conclusions by the SBU].	2006-01-18	16408394
The role of serendipity in drug discovery.	2006	17117615
Roles for C16-ceramide and sphingosine 1-phosphate in regulating hepatocyte apoptosis in response to tumor necrosis factor-alpha.	2005-07-29	15946935
Organophosphorothionate pesticides inhibit the bioactivation of imipramine by human hepatic cytochrome P450s.	2005-06-15	15922009
Prediction of genotoxicity of chemical compounds by statistical learning methods.	2005-06	15962942
Exacerbation of harmaline-induced tremor by imipramine.	2005-05	15894058
UDP-glucuronosyltransferase 1A4 polymorphisms in a Japanese population and kinetics of clozapine glucuronidation.	2005-05	15708967
[Influence of chronic melipramine administration abolition on locomotion and defensive conditioned reflexes in passive and active avoidance in rats].	2005-04-15	15828425
Imipramine-induced syndrome of inappropriate antidiuretic hormone secretion.	1991-12	1749990
Rabbit syndrome, antidepressant use, and cerebral perfusion SPECT scan findings.	1991-11	1786266
Painful ejaculation associated with antidepressants in four patients.	1991-11	1744063
Lithium and calcium channel blockers: possible neurotoxicity.	1991-09-15	1932412
Pediatric cardiovascular effects of imipramine and desipramine.	1991-01	2005043
Biphasic effects of imipramine in experimental models of epilepsy.	1976-06	181243
The antinicotinic effects of drugs with clinically useful sedative-antianxiety properties.	1975	1803

Patents

Sample Use Guides

In Vivo Use Guide

Usual Adult Dose for Depression Tablets: Initial dose: 100 mg orally per day Maintenance dose: 100 to 200 mg orally per day (If no response after 2 weeks, increase to 250 to 300 mg per day) Maximum dose: 300 mg orally per day

Route of Administration: Oral

In Vitro Use Guide

The inhibition percentage of human PON1 for imipramine was 15.6% at 100 ug/L after incubation for 1 h). At 350 ug/L, the inhibition percentage for imipramine 19.2% after 1 h and 20.2% after 2 h.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:48:47 GMT 2025` Edited by `admin` on `Mon Mar 31 17:48:47 GMT 2025`
Record UNII	MC34P30298
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

IMIPRAMINE EMBONATE

Preferred Name

English

IMIPRAMINE PAMOATE

Common Name

English

IMIPRAMINE EMBONATE [MART.]

Common Name

English

IMIPRAMINE PAMOATE [VANDF]

Common Name

English

IMIPRAMINE PAMOATE [USP MONOGRAPH]

Common Name

English

4,4'-METHYLENEBIS(3-HYDROXY-2-NAPHTHOIC) ACID, COMPOUND WITH 10,11-DIHYDRO-N,N-DIMETHYL-5H-DIBENZ(B,F)AZEPINE-5-PROPYLAMINE (1:2)

Common Name

English

TOFRANIL-PM

Brand Name

English

2-NAPHTHALENECARBOXYLIC ACID, 4,4'-METHYLENEBIS(3-HYDROXY-, COMPD. WITH 10,11-DIHYDRO-N,N-2-NAPHTHALENECARBOXYLIC ACID, 4,4'-METHYLENEBIS(3-HYDROXY-, COMPD. WITH 10,11-DIHYDRO-N,N-DIMETHYL-5H-DIBENZ(B,F)AZEPINE-5-PROPANAMINE (1:2)

Common Name

English

IMIPRAMINE PAMOATE [ORANGE BOOK]

Common Name

English

Imipramine embonate [WHO-DD]

Common Name

English

IMIPRAMINE PAMOATE [MI]

Common Name

English

IMIPRAMINE PAMOATE [USP-RS]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C94727